Monday, 8 June 2020

Rectovaginal Fistula Market Leading Rectovaginal Fistula Market Key Developments Trends, Analysis And Forecasts Till 2023

Market Scenario
As per the Birth Injury Guide, estimates show that between 700 and 900 women die every year due to pregnancy or childbirth-related complications in United States.
Additionally, the growing research and development expenditure by the government as well as private sector is likely to contribute to the market growth. However, the high cost of surgery may restraint the market trends growth during the assessment period.  
Due to increasing focus on research and development in treatment of diseases, moreover increasing applications in cancer treatment are the factors responsible to boost the market growth during assessment period. Companies are using a Rectovaginal Fistula market trends of strategic alliance and acquisition to gain the market and minimize the competition in the market.
The Global Rectovaginal Fistula Market held a market value of USD 950 million in 2017 and is projected to grow at a CAGR of 5.4% over the forecast period. 
Key players
Some of the prominent players in the global rectovaginal fistula market are Cook Medical, Takeda Pharmaceutical Company, Johnson & Johnson Services Inc., Pfizer Inc., Allergan, AbbVie Inc, Novartis International AG, Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche, Eli Lilly and Company, GlaxoSmithKline plc, Sanofi S.A, and others
Segmentation
The global rectovaginal fistula market has been segmented into diagnosis, treatment, and end user.
Based on treatment, the market has been segmented into medications and surgery. Medications is further segmented into antibiotics and infliximab. Rectovaginal Fistula Surgery is further segmented into sewing an anal fistula plug or patch of biologic tissue into the fistula, using a tissue graft, repairing the anal sphincter muscles, performing a colostomy before repairing a fistula in complex or recurrent cases.
By diagnosis, the market has been segmented into physical exam, contrast tests, blue dye test, computerized tomography (CT) scan, magnetic resonance imaging (MRI), anorectal ultrasound, anorectal manometry, and others.
The rectovaginal fistula market, by end user, has been segmented into hospitals & clinics, diagnostic centres, academic institutions and research organizations, and others.
The global rectovaginal fistula market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rectovaginal fistula market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.         
The European rectovaginal fistula market has been segmented into Western Europe and Eastern Europe. The Western Europe rectovaginal fistula market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.      
The rectovaginal fistula market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rectovaginal fistula market in the Middle East & Africa has been segmented into the Middle East and Africa.       
Regional Market Summary
On regional basis, the Americas is anticipated to dominate the global rectovaginal fistula market owing to the growing R&D budgets by both government as well as commercial pharmaceutical and biotechnological companies and increasing adoption of advanced technologies in the region.  Europe is expected to hold the second largest position in the global rectovaginal fistula market owing to the presence of strong academic & research base and availability of funding for research in the European countries. Asia Pacific has served an opportunity for rectovaginal fistula market in this region due to increasing demand for the better treatment and devices and increasing prevalence of disease like cancer. The Middle East & Africa has the least share of the global rectovaginal fistula market. Moreover, the major market share of the region is expected to be held by the Middle East region owing to the increasing government initiatives for the healthcare sector.   
Posted by at No comments:

International Automatic Pill Dispenser Market 2019 Estimation And Forecasts Up To 2023

Automatic Pill Dispenser Market Highlights:
The Global Automatic Pill Dispenser Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 1,700 million in 2018 and is projected to register a CAGR of 7.3% over the forecast period.
The increasing prevalence of cardiovascular disorders and growing older population are the key factors driving the automatic pill dispenser machine market. As per the report published by the Centers for Disease Control and Prevention (CDC) in 2017, nearly 92.1 million adults were dealing with at least one type of cardiovascular disease.
Various other factors such as the advancements in automatic pill dispenser, increasing geriatric population, untapped emerging markets, rise in regulatory approvals, and increasing investment on home care centers are also expected to propel the growth of the market.
However, the high cost of the system can hamper market growth over the forecast period.
Key Players:
Some of the key players in the global automatic pill dispenser market are Baxter International Inc, Becton, Dickinson and Company, Cerner Corporation, Capsa Healthcare, McKesson Corporation, Omnicell Inc., ScriptPro LLC, Swisslog Holdings AG, Yuyama Co.Ltd. Talyst, Inc., and others
Segmentation:
The global automatic pill dispenser market is segmented based on type, end user, and region.
The global market for automatic pill dispenser, by type, is segmented into a centralized, automated dispensing system, and decentralized the automated dispensing system. The centralized, automated dispensing system is further classified into robotic automated dispensing systems, and carousels. Furthermore, decentralized automated dispensing system is classified into a pharmacy-based automated dispensing system, ward-based automated dispensing system, and automated unit dose dispensing system.
Based on end user, the market is segmented into hospital pharmacy, retail pharmacy, and home healthcare.
In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and African region.
The automatic pill dispenser market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European automatic pill dispenser market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The automatic pill dispenser market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The automatic pill dispenser market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Analysis:
The Americas dominated the global market for automatic pill dispenser owing to the rising geriatric population within the region. As per the data suggested by the United Census Bureau, by 2060, the US is projected to grow by 79 million people, from about 326 million today to 404 million. The population is projected to cross the 400-million threshold in 2058. Additionally, according to the WHO, in the US, more than 20% of the total population is likely to be aged 65 years or over by 2030. Rising participation of market players is also strongly impacting the growth of the Americas automatic pill dispenser market. Moreover, the rising prevalence of chronic disorders such as cardiovascular disorders, cancer, diabetes, and others are driving the growth of the market. For instance, according to the National Cancer Institute, in 2016, in the US, 15.5 million new cases of cancer were registered, and approximately USD 147.3 billion were spent for cancer care.
In 2018, it was estimated that Europe stood second in the global automatic pill dispenser market. Technological advancements, along with the availability of funding opportunities in research and innovation, will support market growth.
Asia-Pacific (APAC) is expected to represent the phenomenal market growth throughout the forecast period due to rising prevalence of chronic conditions, growing awareness about medications, and increasing healthcare expenditure. During 2016-2017, Australia spent nearly USD181 billion on health, which is more than USD 7,400 per person and 10% of overall economic activity.
On the other hand, the Middle East and Africa held the least share in the global automatic pill dispenser market due to the low economic development, especially within the African region.
Posted by at No comments:

ELISpot and FluoroSpot Assay Market 2019 – Leading Manufactures, Regions, Drivers, Analysis And Forecasts Till 2023

Market Scenario:
ELISpot and FluoroSpot assays are techniques which are used to assess the antibody reactivity at the cellular level. They are extensively used by hospitals as well as research institutes for early detection of various diseases, most commonly for tuberculosis or viral infection. FluoroSpot assay is an adaptation of the ELISpot assay and has gained widespread acceptance. Market Research Future (MRFR) has extensively studied the patterns and trends governing the global ELISpot and FluoroSpot assay market analysis forecast between 2018-2023 in a detailed report. MRFR has asserted that the market is likely to reach USD 287 Mn at a splendid CAGR of 16.2% over the forecast period. The market stood at USD 135 Mn in 2017.
ELISpot and FluoroSpot assays are outstandingly sensitive and are easy to perform due to which they find extensive application in research studies concerning vaccine development, allergies, cancer, and other research purposes. The surge in the incidence rate of chronic diseases has been instrumental in the growth of the market. Increasing disease burden necessitate the development of vaccines which induce demand for ELISpot and FluoroSpot assays. Additionally, the growing occurrence of oncological diseases has further boosted the market growth. ELISpot and FluoroSpot Market Trends and Technological advances in techniques have resulted in increased sensitivity, robustness, and ease of performance which has increased the adoption rate of these techniques. Other factors motivating growth within the market include an increase in a number of clinical trials and increasing healthcare expenditure across the globe. However, the growth of the market might be hindered by factors such as lack of techniques with adequate knowledge to perform these tests and the availability of alternative detection technologies.
Key players:
Some of the key players in the global ELISpot and FluoroSpot Assay market are Oxford Immunotec (UK), Cellular Technologies (US), Mabtech (Sweden), Becton, Dickinson and Company (US), and Abcam (UK)Bio-Techne (US), Autoimmun Diagnostika (Germany), Biotech Investissement (France), Lophius Biosciences (Germany), and U-CyTech (Netherlands), and Others.
Segmentation:
The Global ELISpot and FluoroSpot Assay Market is segmented on the basis of product, application, and end-user. The ELISpot and FluoroSpot Assay market, by product is categorised into various assay kit, analyzer, ancillary products. The assay kit is sub-segmented into T Cell assay and B Cell assay. On the basis of application, the market is segmented into transplant, vaccines development, clinical trials, cancer treatment. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centres, diagnostic centres, research centers, and others.
Regional Analysis:
Europe stood second largest in the ELISpot and FluoroSpot Assay market owing to the increasing number of pharmaceutical companies, rising in the development of innovative vaccines for the treatment of various viral diseases. The growing funding from government and private agencies for drug development also support the ELISpot and FluoroSpot Assay market in this region.  Asia-Pacific was estimated to be the fastest growing region for the global ELISpot and FluoroSpot Assay market in 2017. The market is expected to witness growth owing to the rising prevalence of viral infection, increasing geriatric population in this region and growing demand for ELISpot and FluoroSpot Assay in research field.
The Middle East and Africa holds the least share in the global ELISpot and FluoroSpot Assay market due to the presence of low health expenditure, lack of skilled technicians and less pharmaceutical company in this region. However, the market is expected to witness growth due to increasing research & development in the Middle East.
Posted by at No comments:

Cerebral Palsy Market Shares Analysis, Key Development Strategies And Forecasts Till 2023

Market Scenario
Cerebral palsy (CP) is a group of lifelong neurological disorders that affect movement and coordination, caused by damage to or abnormalities inside the developing brain of the infant. CP can occur before, during or soon after birth. Additionally, cerebral palsy can develop from several factors such as lack of oxygen to the brain, genetic conditions, brain infections, brain hemorrhage, chemical or substance abuse during pregnancy, injury to the head, and severe jaundice.
The global cerebral palsy market is driving owing to the growing prevalence of cerebral palsy coupled with increasing awareness about the condition. Moreover, the growing adoptions of medications for controlling the symptoms of the cerebral palsy are anticipated to propel the market growth. Additionally, increasing expenditure for the healthcare sector in developed economies and increasing insurance coverage contribute to the growth of the market.
Despite the drivers, side effects associated with medications and high treatment cost and lack of awareness in some developing regions may hamper the market growth during the assessment period.
Regional Summary
The Americas is expected to dominate the global cerebral palsy market during the forecast period owing to the well-established healthcare sector, growing awareness about CP, and the rising prevalence of cerebral palsy in the region. The European market is expected to be the second-largest market due to the growing healthcare expenditure and increasing prevalence of cerebral palsy. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to the developing healthcare infrastructure, and favorable government initiatives for the healthcare sector. The Middle East & Africa is likely to account for the least cerebral palsy market share over global market owing to the lack of economic development, especially in the African region.
Key players
Some of the prominent players in the global cerebral palsy market are Allergen Plc, Cellular Biomedicine Group, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, Acorda Therapeutics, Inc., Medtronic, Meridigen Biotech Co., Ltd., GW Pharmaceuticals Plc, and Cell Cure Neurosciences Ltd.
Segmentation
The global cerebral palsy market has been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has been segmented into spastic cerebral palsy, dyskinetic cerebral palsy, hypotonic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy.
The market, by diagnosis, has been segmented into imaging tests and others. The imaging tests have been further segmented into magnetic resonance imaging (MRI), cranial ultrasound, computed tomography, and electroencephalogram.
The market, by treatment, has been segmented into therapy, medication, surgery, and others. The therapy segment has been segmented into nutrition therapy, hyperbaric oxygen therapy, occupational therapy, physical therapy, stem cell therapy, and others. The medication segment has been segmented into anti-convulsant drugs, muscle relaxants, anti-depressant drugs, anti-inflammatory drugs, and others. Further, the surgery segment has been segmented into orthopedic surgery and others.
Posted by at No comments:

Worldwide Distraction Osteogenesis Devices Market 2019 Synopsis With Leading Players, Industry Growth Factor Foresight By 2023

Market Highlights
Distraction osteogenesis (DO), also called callus distraction, callotasis, osteodistraction, and distraction histogenesis is a surgical process used to reconstruct skeletal deformities and lengthen the bones of the body. Rising incidence and prevalence rates of birth defects boost the market growth whereas various risks involved with the distraction osteogenesis surgery hinder the market growth. According to the survey carried out by Craniosynostosis and Positional Plagiocephaly Support (CAPPS) Organization, 2014, the incidence of craniosynostosis is around 1 in 2,000/3,000 births, accounting for 175 infants born each day, with craniosynostosis globally.
Regional Analysis
North America is expected to dominate the global distraction osteogenesis devices market owing to increasing number of procedures for treating facial abnormalities in the US. The European market is expected to be the second-largest due to increase in initiatives taken by public and private organizations in this field. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the assessment period owing to the expansion of the prominent players along with setting the subsidiaries in these markets. The market in the Middle East & Africa is likely to account for the smallest share of the global distraction osteogenesis devices market.
Segmentation
The global distraction osteogenesis devices market has been segmented into device type, age, application, and end-user.
The market, based on device type, has been segmented into mandibular distraction devices, palatal distraction devices, alveolar distraction devices, craniofacial distraction devices, Lefort distraction devices, small bone distraction devices, and others.
The market, based on craniofacial distraction devices, has been further segmented into external and internal distractors. The market, based on external distractors is further classified into unidirectional distractors, bidirectional distractors, and multiplanar distractors whereas the market, based on, internal distractors can be classified into tooth-borne distractors, bone-borne distractors, and hybrid distractors. The market, by age, has been segmented into pediatrics and adults. The market, by application, has been segmented into dentistry, podiatry, orthopedics, and others. The market, by end-user, has been segmented into hospitals, orthopedic clinic, and others.
Key Players
Some of the key players in the global distraction osteogenesis devices market are Johnson & Johnson Services, Inc., Zimmer Biomet Holdings, Inc., Stryker Corporation, KLS Martin Group, Osteomed, Acumed LLC, Jeil Medical Corporation, Ningbo Cibei Medical Treatment Appliance Co., Ltd. Ortho Max Manufacturing Company Pvt. Ltd., Ortho-Care, and Titamed.
Posted by at No comments:

Covid-19 Impact On CBD Market In-Depth Analysis With Current Trends And Future Estimations

Market Research Future (MRFR) collected data on several factors including implications of covid-19 impact on microbiome sequencing services market and demographic challenges, showed how it could move forward in the coming years.
The Global CBD Market was valued at USD 570 Million in 2018 and is expected to register a CAGR of 125.58% during the forecast period.
Cannabidiol (CBD) is a safe, non-addictive substance found in the cannabis plant. CBD is the second-most abundant cannabinoid found in cannabis after tetrahydrocannabinol (THC). CBD has significant therapeutic benefits such as anti-inflammatory, analgesic, anti-anxiety, and seizure-suppressant properties. According to a survey by the National Center for Biotechnology Information (NCBI) conducted between 2017 and 2018, about 62% of the population used CBD to treat a medical condition.
The growing research & development and financial support by various private and government organizations for cannabinoid research, rising occurrence of chronic diseases and related complications, and legalization of CBD in various regions are expected to have a positive impact on the global cannabidiol (CBD) market. However, adverse effects associated with cannabis and stringent government policies are anticipated to restrain the growth of the global CBD market.
Unique Formulation of CBD is Being Tested for its Efficacy in Treating Viral Infections, including COVID-19.
The CBD terpene formulation is exclusively dedicated to the treatment and prevention of viral infections. It is precisely designed for high-risk populations and the prevention of infections such as the COVID-19 novel strain of coronavirus. In previous research projects that were undertaken since the outbreak of the SARS virus in 2002, CBD terpenes are effective antiviral agents and specific terpenes that came into contact with the SARS virus were found to decrease its severity and influence (both in-vitro and in-vivo) by withholding a certain protein that replicates the RNA. This prevents it from penetrating healthy cells and using them as hosts for its replication.
The novel formulation is intended to be consumed by direct inhalation. For instance, the Chairman of CannaSoul, Professor Dedi Meiri of the Israel Institute of Technology, said: “Our lab has been permitted to operate as a corona lab, and in doing so, we are encouraging two studies based on existing cannabis studies.
First, we will try to detect the plant’s molecules that are capable of overpowering the immune response to the COVID-19 pandemic, which causes inflammation and severe disease to lower the immune system response without suppressing it, thereby providing better corresponding treatment to the steroids, which completely suppress the immune system.
The second study is looking at the ACE2 receptor, which allows the virus to inject its genetic expression into human cells and proliferate. Moreover, as per Eybna’s CEO, Nadav Eyal, “This type of delivery method is a game-changer, empowering us to achieve therapeutic qualities from these unique phytochemicals like never before.”
We have observed the massive impact of novel coronavirus on people’s lives over the last five months. It has also impacted various industries across the globe, eventually affecting the global economy. Some industries have experienced negative growth, whereas some industries have experienced tremendous demand and have generated massive revenues in this period. Covid 19 Impact on CBD market is the one of the positive impact sector on global industry

CBD Market Dynamics
Growing research and development activities and financial support by various private and government organizations for cannabinoid research- There are many private and government organizations supporting the research and development for cannabinoids for medical purposes. Cannabis has numerous medicinal properties by which it can cure various diseases. According to the National Institute of Drug Abuse, May 2018 publication, in 2017, the National Institute of Health (NIH) supported 330 projects and spent USD 140 million on cannabinoid research and development. During this investment, USD 36 million was spent on 70 projects to examine the therapeutic properties of cannabis, and USD 15 million was spent on 26 projects centered on cannabinoid (CBD). Even in 2016, NIH spent USD 21 million studying the therapeutic properties of cannabinoids. Singapore, known for the world's most stringent drug laws, is also funding research projects on medical treatments containing synthetically derived compounds of the cannabis plant. In 2017, the government-run National Research Foundation launched a program to research the therapeutic potential of cannabinoids.
Segmentation
On the basis of form, the global cannabidiol market is segmented into solid and liquid.
In the solid form of CBD, the report covers CBD crystals, CBD wax, capsule/softgel, hash, and others. The liquid form of CBD includes CBD oil, tincture, cream, e-liquid, and others.
CBD crystals are a pure form of CBD isolates. CBD crystals are produced by heating CBD rich extract and then continuous cooling and separating it. CBD crystals are generally used to manufacture CBD infused edibles and creams. CBD wax is solidified or crystalized full spectrum form of CBD. CBD wax is a highly concentrated form of CBD and especially used for pain relief. CBD capsules are similar in comparison to capsules as they are surrounded by an outer shell, usually gelatin. CBD soft gelatin capsule is a translucent golden shade standard capsule that is filled with hemp oil and sometimes olive oil as filler.
CBD oil is one of the most popular and widely available forms of CBD. It is specifically used for medical purposes as it provides fast and effective results. There are a wide variety of flavors of full spectrum CBD oils available in the market. CBD tinctures are made from high strains of hemp, with 60-70% of alcohol. CBD tinctures are primarily used to relieve anxiety and ease the pain. CBD infused e-liquid are used as a fluid in electronic cigarettes and vaporizers.
CBD Market Key Players
The prominent players in the global CBD market are Aphria Inc., Folium Biosciences, Freedom Leaf, Inc, Green Roads of Florida, LLC, CBD Health Solutions, LLC, ENDOCA, Isodiol International Inc, CV Sciences, Inc, Medical Marijuana, Inc., Canopy Growth Corporation, Elixinol Global Limited.
The players operating in the global CBD market are focusing on product launches, along with expanding their global footprints by entering untapped markets.
CBD Market Regional Analysis
The Americas dominate the global CBD market, owing to the increasing consumption of cannabis-based products. According to the World Health Organization (WHO), the consumption of marijuana has an annual prevalence rate of nearly 2.5% of the global population, i.e., approximately 147 million individuals. It is also reported that approximately 22.2 million Americans of 12 years of age and older use cannabis and related products for various reasons.
Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @
Europe holds the second largest market share due to the rising awareness about clinical applications of cannabis. CBD is legal and can be openly marketed in certain European countries, for instance, the Ministry of Agriculture, Food and Forestry, and the Bulgarian Food Safety Agency issued the ‘free certificate of sale’ for the CBD products. Thus, such approvals and consideration by the regulatory agencies in Europe are driving the CBD market growth in the region. In spite of the approvals and considerations, there are positive restrictions associated with the use of the products. For instance, in 2013, medical cannabis was legalized in the Czech Republic, but it was limited to 180 grams of dry matter per month. In Europe, marijuana and cannabis laws differ from country to country. Previously, Germany was importing medical cannabis from other countries, but in 2017, Germany passed a law to expand access to medical cannabis and to allow domestic production. Increasing participation of various companies such as Medical Marijuana Inc., as a scope of development, announced the formation of Canipa Holdings in Romania, European Union. The effect of such initiatives by the companies is facilitating the growth of the CBD market in the European region.
The Asia-Pacific region is classified into China, India, Japan, and Rest of Asia-Pacific. It holds the third largest position in the CBD market. Recently, China has legalized the cultivation of CBD (Hemp) and extraction for the derived product. The products are exported and not sold in China. Yunnan provincial government and Public Security Bureau approved the first industrial hemp plant extraction factory in China. It is the largest country in terms of area, population, businesses, and others. The entry of Chinese companies in the CBD market has created a great potential for expansion and growth. In Asia-Pacific, cannabis-based products are completely unacceptable. But due to the increasing cases of epilepsy, cannabis-based products are prescribed by some physicians. For instance, a recent Australian nationwide survey of 976 people with epilepsy indicated that 13% of the parents were using illicit cannabis extracts to manage their child’s seizures. Australia mainly focuses on the medical use of cannabis products. Australian regulatory agencies are operating on providing a guideline for the use of the CBD products. This is expected to help in the growth of the CBD market in Australia.
The Middle East and Africa is expected to witness a restricted growth due to stringent government policies, adverse effects associated with cannabis, and the illegal use of marijuana. In the Middle East, few of the Arab countries are imposing trick laws over the use and handling of cannabis-related products. Thus, the CBD market in these regions has limited scope for growth during the forecast period.
Posted by at No comments:

Mixed Reality in Healthcare Market Swot Analysis, Major Key Players Revenue, Analysis And Forecasts To 2023

Market Highlights
Mixed Reality (MR) is a combination of Augmented Reality (AR) and Virtual Reality (VR), defining the polar ends of a spectrum known as virtuality spectrum or mixed reality spectrum. Augmented reality delivers digital components, whereas virtual reality enables immersive imitation of real-life settings. MR has widespread applications in different fields of healthcare, varying from treatment to training and education. It is estimated that the global mixed reality in healthcare market is expected to register a CAGR 26.3% during the forecast period of 2019 to 2024, with an estimated market value of USD 2,475 million in 2024.
Numerous factors such as rapid improvements in the adoption of sensor technology, increase in the user acceptance, increased applications of MR in disease care and treatment, and increasing workload of healthcare professionals are anticipated to fuel the growth of the market. Additionally, the benefits of MR systems such as operational efficiency, increased service quality, and reduced human effort is also projected to drive market growth. On the other hand, the lack of adequate skill among medical practitioners, high investment costs, occurrences of technical glitches and the concern related to loss of data is likely to curb the growth of the market during the assessment period.
The global mixed reality in healthcare market is currently dominated by several market players. The important players in the market are involved in new product launches and strategic collaborations to strengthen its market position. For instance, in March 2018, Samsung announced a partnership with Travelers Insurance, Cedars-Sinai Medical Center, Bayer, and AppliedVR to study a virtual reality for pain management.
Segmentation
The global mixed reality in healthcare market has been segmented into component, device type, application, and end user. The market, based on component, has been segmented into software, hardware, and service. The market, by device type, has been segmented into augmented reality in healthcare and virtual reality in healthcare. The market, by augmented reality in healthcare, has been further segmented into head-mounted display (HMD), and handheld device. The market, by virtual reality in healthcare, has been segmented into head-mounted display (HMD), gesture tracking devices, projectors, and others. The market, by application, has been segmented into surgery simulation, surgery, patient care management, pharmacy care management, fitness management, and others. The market, by end user, has been segmented into hospital and surgical centers, research organizations, and others.
Key Players
Some of the key players in the global mixed reality in healthcare market are Mindmaze, Atheer, Augmedix, Firsthand Technology, Daqri, Medical Realities, Google, Microsoft, Echopixel, Oculus VR, Orca Health, Psious, Samsung Electronics, Surgical Theatre LLC, and Osso VR.
Regional Analysis
The market in the Americas is expected to dominate the global mixed reality in healthcare market during the forecast period owing to the increasing per capita healthcare expenditure, and the heavy adoption of new technology in the region. Europe is expected to hold the second largest position in the global mixed reality in healthcare market. The market growth in this region is because of the presence of a well-established healthcare system and increase in life-threatening diseases. Asia-Pacific is estimated to be the fastest growing region in the market due to the huge patient pool and rising government initiatives of healthcare reforms. In 2016, as a part of an ongoing neurosurgical collaboration between Children’s Hospital in Ho Chi Minh City (Vietnam) and Children’s of Alabama Hospital, a Virtual Interactive Presence and Augmented Reality (VIPAR) telecommunication system was implemented at both hospitals to provide intraoperative assistance to medical professionals. However, less capital investment is restricting the market growth of this region. The market in the Middle East & Africa is likely to account for the smallest share of the global mixed reality in healthcare market. The market growth in this region is restricted due to the low disposable income in the region.
Posted by at No comments:
Subscribe to: Posts (Atom)